Timber Pharmaceuticals, Inc.
TMBR · AMEX
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.00 | -0.00 | 0.00 |
| FCF Yield | -426.08% | -895.51% | -1,039.32% | -394.45% |
| EV / EBITDA | 0.34 | 1.05 | 2.37 | 3.21 |
| Quality | ||||
| ROIC | 192.62% | -212.91% | -64.21% | -38.35% |
| Gross Margin | 0.00% | 0.00% | -2,425.90% | 0.00% |
| Cash Conversion Ratio | 0.65 | 0.96 | 0.88 | 1.30 |
| Growth | ||||
| Revenue 3-Year CAGR | -31.06% | 436,416.92% | – | -100.00% |
| Free Cash Flow Growth | 31.98% | -22.21% | 22.67% | 26.04% |
| Safety | ||||
| Net Debt / EBITDA | 0.49 | 1.16 | 2.45 | 3.55 |
| Interest Coverage | -61.43 | -63.52 | -58.53 | -43.92 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -59.42 | -38.59 | -57.86 | -47.93 |